Clinical trials
Alzheimer s Disease clinical trials
Below are recruiting alzheimer s disease clinical trials, each written for real people, not researchers. We’re tracking 595 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03019757Recruiting
Testing ways to tell dementia causes apart
This study looks at how to distinguish Alzheimer’s disease, Lewy body dementia, and Parkinson’s disease when someone has memory and thinking problems. It may help doctors choose the most accurate diagnosis and treatment path for the right condition.
Columbus, OhioAges 18 years+ - NCT06869135Recruiting
Saliva testing for brain diseases
This trial is collecting saliva samples from people with Alzheimer's, Parkinson's, or other brain diseases to find new ways to diagnose them. It may help improve early detection.
Florence, FIAges 45 years+ - NCT07758595RecruitingPhase 1
Study of DNL921 for healthy people and people with Alzheimer's disease
This trial tests an investigational drug called DNL921 in healthy volunteers and in people with mild to moderate Alzheimer's disease. The goal is to see if it is safe and how the body handles it, which is a first step in finding a new treatment.
ManchesterAges 18–75 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Birmingham, AlabamaAges 50–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Homewood, AlabamaAges 55–90 - NCT06924359Recruiting
Eye scans and blood tests for early Alzheimer's detection
This study uses special eye scans and blood tests to find early signs of Alzheimer's disease. It aims to detect the disease before memory loss becomes severe, so treatment can start sooner.
BeijingAges 50 years+ - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT06889896Enrolling by invitation
Blood test for Alzheimer's brain changes
This study uses a simple blood test to quickly detect Alzheimer's-related brain changes (amyloid plaques). It may help people with memory concerns avoid a more invasive PET scan and get answers faster.
Hefei, AnhuiAges 45–85 - NCT07324161Recruiting
Magnetic Brain Stimulation for Alzheimer's Disease
This trial tests whether a non-invasive magnetic brain stimulation treatment (TMS) can help people with mild to moderate Alzheimer's disease. You would receive the treatment and be monitored for safety and benefit.
Fuzhou, FujianAges 50–90 - NCT07632755Recruiting
Memory Training Using Movement for Early Alzheimer's Disease
This study tests whether learning memory strategies through physical movement and motor activities can help people with early Alzheimer's disease improve their memory. Researchers will compare people with early Alzheimer's to healthy older adults to see if this approach is effective.
GrenobleAges 60 years+ - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT07633470RecruitingPhase 4
Zunveyl for Alzheimer's disease symptoms and caregiver support
This study tests a medication called Zunveyl to see if it helps reduce behavioral and neuropsychiatric symptoms in people with mild-to-moderate Alzheimer's disease, and whether it reduces stress on family caregivers. You would need a confirmed Alzheimer's diagnosis supported by a blood test, and a dedicated caregiver who can attend visits and report on your symptoms.
Miami, FloridaAges 50 years+ - NCT07007208RecruitingPhase 2
Brain imaging study to detect early Alzheimer's risk
This study uses brain scans (MRI and PET) to look at a tiny brain region called the locus coeruleus, which may show early signs of Alzheimer's disease. Researchers want to see if changes in this area are linked to thinking skills and future memory decline.
ToulouseAges 60–100 - NCT04312399Recruiting
Hormone treatment study for Alzheimer risk in postmenopausal women
This study looks at whether hormone treatment can help prevent or slow Alzheimer’s disease in women who have gone through menopause. It may help by testing a hormone-based approach in a carefully selected group.
GhentAges 40–65 - NCT04629547RecruitingPhase 2
Sleep study to help prevent Alzheimer’s disease
This trial tests whether treating sleep issues and measuring sleep can help lower the risk of Alzheimer’s disease before it starts. It focuses on older adults with no dementia signs yet.
St Louis, MissouriAges 65 years+ - NCT06274528RecruitingPhase 2
DORA and lemborexant in Alzheimer's biomarkers study
This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.
St Louis, MissouriAges 65 years+ - NCT05020106Recruiting
Tests Alzheimer’s core blood/brain markers to set diagnostic cutoffs
This study checks Alzheimer’s “core biomarkers” to find the best cut-off values for diagnosing Alzheimer’s disease and related conditions. It may help doctors more accurately tell Alzheimer’s, mild cognitive changes, and other causes of memory problems apart.
Beijing, Beijing MunicipalityAges 55–75 - NCT05059158Recruiting
Study how the brain clears amyloid in Alzheimer’s
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
München, BavariaAges 50–85 - NCT05205980Recruiting
Training practice to help prevent falls in Alzheimer’s
This trial tests whether a specific “training practice” can reduce falls in people with probable Alzheimer’s disease. It may help by improving safe walking and balance after doing the training.
Valdosta, GeorgiaAges 65–90 - NCT05573490Recruiting
Lifestyle program study for early-onset Alzheimer’s
This study tests a structured lifestyle intervention to help people with early-onset Alzheimer’s disease. It is designed for adults with confirmed Alzheimer’s-related brain changes, and may help with symptoms or day-to-day functioning.
Indianapolis, IndianaAges 40–75 - NCT05908695RecruitingPhase 4
GV-971 treatment for mild to moderate Alzheimer’s disease
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
Huainan, AnhuiAges 50–85 - NCT07694921Enrolling by invitation
Non-invasive brain stimulation for Alzheimer's disease
This trial tests if a safe, non-invasive electrical stimulation can help people with Alzheimer's disease. It aims to improve thinking and memory skills.
Hangzhou, ZhejiangAges 60 years+
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer s disease?
- Yes. Clin2 currently lists 595 recruiting alzheimer s disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer s disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer s disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.